2012
DOI: 10.1182/blood.v120.21.3548.3548
|View full text |Cite
|
Sign up to set email alerts
|

The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity

Abstract: 3548 The TNF/TNF receptor (TNFR) family comprises various molecules that substantially influence cellular functions of both tumor and immune effector cells. The TNFR family member OX40 has been shown to influence proliferation and differentiation of T cells in autoimmune diseases. Here we studied the yet unknown role of OX40 in acute myeloid leukemia (AML). Substantial surface expression of OX40 was detected on malignant cells of AML patients in 24 of 60 (40%) investigated cases. Expression of O… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The results showed that anti-CD22 CAR-T cells can mediate similar potent antineoplastic effects to anti-CD19 CAR-T cells in pre-B ALL patients, and they also exhibit great efficacy in anti-CD19 immunotherapy-resistant patients with loss of or diminished surface expression of CD19 [ 50 , 51 ], indicating that CD markers are extremely important targets (biomarkers) for targeted therapy to eradicate hematologic malignancies. In addition to these, there are also many other sorts of targets, such as CD44 [ 52 ], CD47 [ 53 ], CD117 [ 54 ], CD123 [ 55 ] and CD134 [ 56 ] in acute leukemia, as well as CD20 [ 57 ] in chronic leukemia, which are used as specific targets for leukemia treatment, and several clinical trials are currently ongoing to assess their safety and efficacy in various clinics.…”
Section: CD Markers Are Great Therapeutic Targets For Hematologic Mal...mentioning
confidence: 99%
“…The results showed that anti-CD22 CAR-T cells can mediate similar potent antineoplastic effects to anti-CD19 CAR-T cells in pre-B ALL patients, and they also exhibit great efficacy in anti-CD19 immunotherapy-resistant patients with loss of or diminished surface expression of CD19 [ 50 , 51 ], indicating that CD markers are extremely important targets (biomarkers) for targeted therapy to eradicate hematologic malignancies. In addition to these, there are also many other sorts of targets, such as CD44 [ 52 ], CD47 [ 53 ], CD117 [ 54 ], CD123 [ 55 ] and CD134 [ 56 ] in acute leukemia, as well as CD20 [ 57 ] in chronic leukemia, which are used as specific targets for leukemia treatment, and several clinical trials are currently ongoing to assess their safety and efficacy in various clinics.…”
Section: CD Markers Are Great Therapeutic Targets For Hematologic Mal...mentioning
confidence: 99%